---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-173591"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:58:26.544057+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics enters $200M at-the-market equity offering agreement with TD Cowen

## Summary
- New Sales Agreement with TD Cowen to sell up to $200M of Class A common stock from time to time.
- Prior $200M ATM agreement with TD Cowen terminated effective August 5, 2025.
- TD Cowen will receive up to 3.0% commission on gross proceeds of shares sold.
- Company not obligated to sell any shares; sales subject to company instructions and market conditions.
- Issuance will be made under existing S-3 shelf registration statement.

## SEC filing metadata
- accession: 0001193125-25-173591
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312525173591/0001193125-25-173591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312525173591/d42398d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-173591
- JSON: https://secwatch.observer/filing/0001193125-25-173591.json
- Plain text: https://secwatch.observer/filing/0001193125-25-173591.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.